Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL323729 | 0.85 | HTR6 (0.58) | PSIP1F2TMPRSS4TSHRTP53 | |
| SCHEMBL19110981 | 0.85 | HTR6 (0.58) | PSIP1F2TMPRSS4TSHRTP53 | |
| Hydrochloric Acid SCHEMBL930597 | 0.83 | HTR6 (0.55) | PSIP1F2TMPRSS4TSHRTP53 | |
| Hydrochloric Acid SCHEMBL30184245 | 0.83 | HTR6 (0.55) | PSIP1F2TMPRSS4TSHRTP53 | |
| SCHEMBL7901727 | 0.78 | TDP1 (0.59) | PSIP1F2TMPRSS4TSHRTP53 | |
| Bicarbonate SCHEMBL29219000 | 0.78 | TSHR (0.52) | PSIP1TSHRCA12CA1CA2 | |
| Ethylamine SCHEMBL5875345 | 0.77 | TSHR (0.73) | PSIP1TSHRCYP2D6CA12CA1 | |
| Phosphoric Acid SCHEMBL28712122 | 0.74 | ALDH1A1 (0.48) | PSIP1TSHRCA12CA1CA2 | |
| SCHEMBL29128963 | 0.71 | CA12 (0.60) | TSHRCA12CA1CA2CA9 | |
| Methylamine SCHEMBL28266275 | 0.71 | PSIP1 (0.90) | PSIP1TSHRTP53CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295082-B1 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | FDS PHARMA ASS (GB) | 2013-09-18 | — | — | EP | disclosed |
| EP-1394261-B1 | ANTIGENS FOR IMMUNISATION | FDS PHARMA ASS (GB) | 2011-03-30 | — | — | EP | disclosed |
| EP-2295082-A1 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | FDS Pharma Ass. (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-7560529-B2 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | FDS Pharma (GB) | 2009-07-14 | — | — | US | disclosed |
| WO-2008078177-A2 | METHOD FOR PRODUCING CATALYTIC ANTIBODIES (VARIANTS), ANTIGENS FOR IMMUNIZATION AND NUCLEOTIDE SEQUENCE | FDS PHARMA ASS. (RU) | 2008-07-03 | — | — | WO | disclosed |
| US-20070178109-A1 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | LIFEBIO LABORATORIES LLC | 2007-08-02 | — | — | US | disclosed |
| US-20040265975-A1 | glycoprotein 120; fusion proteins; myelin basic protein; autoimmune diseases; genetic vaccines | FDS PHARMA ASS. (GB) | 2004-12-30 | — | — | US | disclosed |
| EP-1394261-A2 | METHOD FOR PRODUCING CATALYTIC ANTIBODIES (VARIANTS), ANTIGENS FOR IMMUNISATION AND NUCLEOTIDE SEQUENCE | ASGL - Farmatsevticjeskie Innovatsii, Zaptryote Aktsionernoe Obschestvo (RU) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070178109-A1 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | SSB, DNMT3L, NASP | PSIP1 2312/4885F2 893/4885TMPRSS4 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.